GEN Exclusives

More »

GEN News Highlights

More »
Feb 6, 2007

Antisense and Isis Extend Pact

  • Antisense Therapeutics (ANP) and Isis Pharmaceuticals agreed to extend their drug discovery and development collaboration for two years. The original collaboration allows ANP to select, test, and assess new antisense compounds for a variety of diseases and potential commercial markets.

    Through this agreement and its extension, ANP intends to add new products its pipeline, which currently includes ATL1102 for multiple sclerosis and ATL1103 for growth and sight disorders. ATL1103 is a direct product of this active collaboration.

    ANP holds worldwide exclusive licenses to any drug that it ultimately decides to develop and commercialize.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Stopping Research Fraud

What is the best approach to curbing scientific misconduct and outright fraud?